LBL.V - Lattice Biologics Ltd.
| Previous Close | 0.1150 |
| Open | 0.1250 |
| Bid | 0.1450 x N/A |
| Ask | 0.1500 x N/A |
| Day's Range | 0.1250 - 0.1550 |
| 52 Week Range | 0.0200 - 0.2100 |
| Volume | 5,690,972 |
| Avg. Volume | 1,743,911 |
| Market Cap | 13.551M |
| Beta (5Y Monthly) | 1.45 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0100 |
| Earnings Date | Feb. 27, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Lattice Biologics Ltd. Announces Initial Recruitment of Patients for a Phase 1 Clinical Trial to Access Safety and Efficacy of AmnioBoost for Treatment of COVID-19
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) ("Lattice Biologics" or the "Company") announces it has begun enrolling patients in its Phase 1 clinical trial to address safety and efficacy of its novel stem cell technology, AmnioBoost, for the treatment of severe acute respiratory syndrome (SARS) related to COVID-19 infection.
- Business Wire
Lattice Biologics to Evaluate Anti-Inflammatory Stem Cell Therapy Treatment of COVID-19 Lung Disease
Lattice Biologics Ltd. (TSX-V: LBL) (OTCQB: LBLTF) ("Lattice Biologics" or the "Company") today announced that it plans to evaluate its amniotic fluid concentrate, AmnioBoost, in patients with acute respiratory distress syndrome (ARDS) caused by coronavirus (COVID-19)
- Business Wire
Lattice Biologics Announces Planned Debt-to-Equity Conversion
Lattice Biologics Ltd. (TSX-V: LBL) (OTCQB: LBLTF) ("Lattice Biologics" or the "Company") announces that, subject to TSXV approval, the Company plans to convert US $726,200 (Can$1,000,000) of debt (the "Debt") into equity of Lattice Biologics (the "Transaction").
- Business Wire
LATTICE BIOLOGICS LTD. Transferred To TSX Venture Exchange Tier 2
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) ("Lattice Biologics" or the "Company") Lattice Biologics Ltd. announces today that its listing on the TSX Venture Exchange ("TSX-V") has been transferred from the Tier 1 category to the Tier 2 category effective March 5, 2020
- Business Wire
Lattice Biologics Ltd. Reports Q1 2020 Results
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) ("Lattice Biologics" or the "Company") announces financial results for Q1 2020.
- Simply Wall St.
Did Changing Sentiment Drive Lattice Biologics's (CVE:LBL) Share Price Down A Painful 90%?
It's not possible to invest over long periods without making some bad investments. But really big losses can really...
- Simply Wall St.
What Kind Of Share Price Volatility Should You Expect For Lattice Biologics Ltd. (CVE:LBL)?
If you're interested in Lattice Biologics Ltd. (CVE:LBL), then you might want to consider its beta (a measure of share...
- Baystreet
Stocks in play: Lattice Biologics Ltd.
Announced financial results for Q2 2019. Gross profit margin was 77.0% for the three months ended March ...
- Simply Wall St.
Did Changing Sentiment Drive Lattice Biologics's (CVE:LBL) Share Price Down A Painful 85%?
It is a pleasure to report that the Lattice Biologics Ltd. (CVE:LBL) is up 50% in the last quarter. But that doesn't...
